Register to view the archived recording here.
Santaris Inks LNA Rx Deal with Shire, Leveraging Technology in Areas Outside of Core Focus
A Santaris official also said that while the company remains committed to microRNAs as drug targets, the company isn’t likely to advance additional miRNA drugs into the clinic in the near term as it takes a measured approach to selecting future clinical candidates.
New to GenomeWeb? Register here quickly.